PTCT Stock: Price, Earnings History and SEC Filings
PTC Therapeutics, Inc. (PTCT) last traded at $59.97, down 6.97% on the latest session and down 7.4% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.61 against an analyst estimate of $0.17, a beat of 258.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PTCT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.61 | $0.17 | +258.82% |
| Jun 2026 | Jul 30, 2026 | $0.92 | $-0.17 | +641.18% |
| Mar 2026 | May 7, 2026 | $-0.03 | $-0.45 | +93.33% |
| Dec 2025 | Feb 19, 2026 | $-1.67 | $-0.21 | -695.24% |
PTCT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How PTCT reacts to earnings
Across its last 8 earnings releases, PTCT moved 7.6% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | -6.97% |
| 2026-07-30 | After close | -9.94% |
| 2026-05-07 | After close | +14.27% |
| 2026-02-19 | After close | +1.09% |
| 2026-01-12 | Before open | +0.08% |
| 2025-11-04 | After close | +5.98% |
| 2025-08-07 | After close | -9.89% |
| 2025-05-06 | After close | +12.63% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PTCT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.7B | $683M | $702M | 39.4% | $7.78 |
| 2024 | $807M | -$363M | -$114M | -45.0% | $-4.73 |
| 2023 | $938M | -$627M | -$187M | -66.8% | $-8.37 |
| 2022 | $699M | -$559M | -$389M | -80.0% | $-7.79 |
| 2021 | $539M | -$524M | -$280M | -97.3% | $-7.43 |
| 2020 | $381M | -$438M | -$212M | -115.1% | $-6.64 |
| 2019 | $307M | -$252M | -$112M | -82.0% | $-4.27 |
| 2018 | $265M | -$128M | -$35M | -48.4% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PTCT
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 21, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Aug 28, 2026Material agreement
- 8-K · Aug 13, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Officer or director change, Regulation FD disclosure
- 8-K · Jun 18, 2026Material agreement, New financial obligation, Unregistered share sale
- 8-K · Jun 16, 2026Other events, Financial statements and exhibits
- 8-K · Jun 9, 2026Officer or director change, Financial statements and exhibits
Insider filing activity
PTCT insiders filed 11 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PTCT news
- PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To LossOct 31, 2026 · finance.yahoo.com
- PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In FocusOct 30, 2026 · finance.yahoo.com
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 30, 2026 · finance.yahoo.com
- PTC Therapeutics (PTCT) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- PTC Therapeutics boosts 2026 outlook on Sephience surgeOct 30, 2026 · theglobeandmail.com
- Which Gives You More High-Margin Software Growth, PTC Or Fair Isaac?Oct 30, 2026 · trefis.com
- PTC Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.